<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35747798</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>16 Months Follow Up of Patients' Behavior and Mild COVID-19 Patterns in a Large Cohort of Cancer Patients During the Pandemic.</ArticleTitle><Pagination><StartPage>901426</StartPage><MedlinePgn>901426</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">901426</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2022.901426</ELocationID><Abstract><AbstractText><b>Background:</b> Acute severe forms of COVID-19 infection are more likely in cancer patients and growing attention has been given to the persistent symptoms of the disease after severe COVID-19. However, mild illness is the dominant clinical presentation of COVID-19 infection. To investigate patients' behavior and the short- and longer-term pattern of the disease in cancer patients with mild COVID infection, a longitudinal online survey was conducted for 16 months during the pandemic in a large cohort of cancer patients from a French COVID-19 hot spot. An online questionnaire was administered at three time points between the first wave of the pandemic in France and the fourth wave. The questionnaire was completed by 1415 to 2224 patients, which queried patients' demographics, their behavior, and COVID infection patterns. Seventy percent of the patients were female, and 40% had a comorbid condition. More than one-third of the participants had breast cancer, and half were survivors. The rate of infection was 30% during wave 1 and 10% in wave 4; most patients had a mild COVID-19 infection. Twenty-five percent of infected patients during wave 4 did not seek medical advice. At wave 4, 87% of the patients received at least one dose of vaccine. Systematic compliance to shielding measures decreased over time. The short-term pattern of mild COVID changed between wave 1 and wave 4. Twenty-two percent of infected patients experienced persistent signs for more than 6 months with a negative impact on sleep, social behavior, and increased consumption of stress-relieving drugs. Our results showed a high prevalence of long-lasting symptoms in cancer patients with mild COVID-19 infection and inadequate behavior toward the disease and prevention measures among patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Hajjaji, Lepoutre, Lakhdar, B&#xe9;court, Bellier, Kaczmarek, Broyelle, Giscard and Lartigau.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hajjaji</LastName><ForeName>Nawale</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medical Oncology department, Oscar Lambret Cancer Center, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm, U1192, Laboratoire Prot&#xe9;omique, R&#xe9;ponse Inflammatoire et Spectrom&#xe9;trie de Masse (PRISM), Univ. Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lepoutre</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Quality department, Oscar Lambret Cancer Center, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakhdar</LastName><ForeName>Sarra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Oncology department, Oscar Lambret Cancer Center, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xe9;court</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Oncology department, Oscar Lambret Cancer Center, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellier</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical Oncology department, Oscar Lambret Cancer Center, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaczmarek</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Medical Oncology department, Oscar Lambret Cancer Center, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broyelle</LastName><ForeName>Antonin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology department, Oscar Lambret Cancer Center, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giscard</LastName><ForeName>Sandrine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Quality department, Oscar Lambret Cancer Center, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lartigau</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Radiotherapy department, Oscar Lambret Cancer Center, Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anti-COVID-19 vaccination</Keyword><Keyword MajorTopicYN="N">cancer patients</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">mild COVID-19 infection</Keyword><Keyword MajorTopicYN="N">patients&#x2019; behavior</Keyword><Keyword MajorTopicYN="N">shielding measures</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>2</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35747798</ArticleId><ArticleId IdType="pmc">PMC9209649</ArticleId><ArticleId IdType="doi">10.3389/fonc.2022.901426</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sharafeldin N, Bates B, Song Q, Madhira V, Yan Y, Dong S, et al. . Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C). J Clin Oncol (2021) 39(20):2232&#x2013;46. doi: 10.1200/JCO.21.01074</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.01074</ArticleId><ArticleId IdType="pmc">PMC8260918</ArticleId><ArticleId IdType="pubmed">34085538</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. . Patients With Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study During the COVID-19 Outbreak. Cancer Discovery (2020) 10(6):783&#x2013;91. doi: 10.1158/2159-8290.CD-20-0422</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-0422</ArticleId><ArticleId IdType="pmc">PMC7309152</ArticleId><ArticleId IdType="pubmed">32345594</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA Oncol (2022) 8(1):69&#x2013;78. doi: 10.1001/jamaoncol.2021.5148</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2021.5148</ArticleId><ArticleId IdType="pmc">PMC8554684</ArticleId><ArticleId IdType="pubmed">34709356</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Rayner C, Delaney B. Fresh Evidence of the Scale and Scope of Long Covid. BMJ (2021) 373:n853. doi: 10.1136/bmj.n853</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n853</ArticleId><ArticleId IdType="pubmed">33795224</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. . Post-Acute COVID-19 Syndrome. Nat Med (2021) 27(4):601&#x2013;15. doi: 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigfrid L, Drake TM, Pauley E, Jesudason EC, Olliaro P, Lim WS, et al. . Long Covid in Adults Discharged From UK Hospitals After Covid-19: A Prospective, Multicentre Cohort Study Using the ISARIC WHO Clinical Characterisation Protocol. Lancet Reg Health Eur (2021) 8:100186. doi: 10.1016/j.lanepe.2021.100186</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100186</ArticleId><ArticleId IdType="pmc">PMC8343377</ArticleId><ArticleId IdType="pubmed">34386785</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. . Characterising Long COVID: A Living Systematic Review. BMJ Glob Health (2021) 6(9):e005427. doi: 10.1136/bmjgh-2021-005427</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA (2020) 324(8):782&#x2013;93. doi: 10.1001/jama.2020.12839</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Thye AY-K, Law JW-F, Pusparajah P, Letchumanan V, Chan K-G, Lee L-H. Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. Biomedicines (2021) 9(10):1303. doi: 10.3390/biomedicines9101303</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9101303</ArticleId><ArticleId IdType="pmc">PMC8533361</ArticleId><ArticleId IdType="pubmed">34680420</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau NVV, Ngoc NM, Nguyet LA, Quang VM, Ny NTH, Khoa DB, et al. . An Observational Study of Breakthrough SARS-CoV-2 Delta Variant Infections Among Vaccinated Healthcare Workers in Vietnam. E Clinical Medicine (2021) 41:101143. doi: 10.1016/j.eclinm.2021.101143</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101143</ArticleId><ArticleId IdType="pmc">PMC8481205</ArticleId><ArticleId IdType="pubmed">34608454</ArticleId></ArticleIdList></Reference><Reference><Citation>
COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19 - NICE, RCGP, and SIGN . Available at: https://www.nice.org.uk/guidance/ng188.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post-Acute and Long-COVID-19 Symptoms in Patients With Mild Diseases: A Systematic Review. Fam Pract (2022) 39(1):159&#x2013;67. doi: 10.1093/fampra/cmab076</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmab076</ArticleId><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscolo-Rizzo P, Guida F, Polesel J, Marcuzzo AV, Capriotti V, D&#x2019;Alessandro A, et al. . Sequelae in Adults at 12 Months After Mild-to-Moderate Coronavirus Disease 2019 (COVID-19). Int Forum Allergy Rhinol (2021) 11(12):1685&#x2013;8. doi: 10.1002/alr.22832</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alr.22832</ArticleId><ArticleId IdType="pmc">PMC9291310</ArticleId><ArticleId IdType="pubmed">34109765</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. . Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open (2021) 4(2):e210830. doi: 10.1001/jamanetworkopen.2021.0830</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. . Attributes and Predictors of Long COVID. Nat Med (2021) 27(4):626&#x2013;31. doi: 10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Ruiz J, Lomel&#xed;n-Gasc&#xf3;n J, Lira-Luna J, P&#xe9;rez-Fragoso A, Tapia-Conyer R, Nu&#xf1;ez-Aguirre M, et al. . FANSY POSTCOV: A Composite Clinical Immunological Predictive Index for Post-COVID-19 Syndrome Unveils Distinctive Features in a Cohort Study of Mild to Critical Patients. Clin Transl Med (2021) 11(11):e623. doi: 10.1002/ctm2.623</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.623</ArticleId><ArticleId IdType="pmc">PMC8611773</ArticleId><ArticleId IdType="pubmed">34841707</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. . Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. Cell (2022) 185(4):881&#x2013;95.e20. doi: 10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentscher KE, Zhou X, Small BJ, Cohen HJ, Dilawari AA, Patel SK, et al. . Loneliness and Mental Health During the COVID-19 Pandemic in Older Breast Cancer Survivors and Noncancer Controls. Cancer (2021) 127(19):3671&#x2013;9. doi: 10.1002/cncr.33687</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.33687</ArticleId><ArticleId IdType="pmc">PMC8419003</ArticleId><ArticleId IdType="pubmed">34161601</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson E, Jones A, Lesser I, Daly M. International Estimates of Intended Uptake and Refusal of COVID-19 Vaccines: A Rapid Systematic Review and Meta-Analysis of Large Nationally Representative Samples. Vaccine (2021) 39(15):2024&#x2013;34. doi: 10.1016/j.vaccine.2021.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.02.005</ArticleId><ArticleId IdType="pmc">PMC7867398</ArticleId><ArticleId IdType="pubmed">33722411</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevallier C, Hacquin A-S, Mercier H. COVID-19 Vaccine Hesitancy: Shortening the Last Mile. Trends Cognit Sci (2021) 25(5):331&#x2013;3. doi: 10.1016/j.tics.2021.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tics.2021.02.002</ArticleId><ArticleId IdType="pmc">PMC7871796</ArticleId><ArticleId IdType="pubmed">33618982</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan RM, Milstein A. Influence of a COVID-19 Vaccine&#x2019;s Effectiveness and Safety Profile on Vaccination Acceptance. Proc Natl Acad Sci USA March 9 (2021) 118(10):e2021726118. doi: 10.1073/pnas.2021726118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2021726118</ArticleId><ArticleId IdType="pmc">PMC7958192</ArticleId><ArticleId IdType="pubmed">33619178</ArticleId></ArticleIdList></Reference><Reference><Citation>Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. . Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA (2022) 327(7):639&#x2013;51. doi:&#xa0;10.1001/jama.2022.0470</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.0470</ArticleId><ArticleId IdType="pmc">PMC8848203</ArticleId><ArticleId IdType="pubmed">35060999</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeid M, Suffiotti M, Pellaton C, Bouchaab H, Cairoli A, Salvad&#xe9; V, et al. . Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. JAMA Oncol (2022) 8(5):e220446. doi: 10.1001/jamaoncol.2022.0446</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2022.0446</ArticleId><ArticleId IdType="pmc">PMC8914885</ArticleId><ArticleId IdType="pubmed">35271706</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldhorn I, Holland R, Goshen-Lago T, Shirman Y, Szwarcwort-Cohen M, Reiner-Benaim A, et al. . Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients With Solid Tumors. Cancer Discovery (2021) 11(10):2430&#x2013;5. doi: 10.1158/2159-8290.CD-21-1072</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-21-1072</ArticleId><ArticleId IdType="pubmed">34475136</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinders Folmer CP, Brownlee MA, Fine AD, Kooistra EB, Kuiper ME, Olthuis EH, et al. . Social Distancing in America: Understanding Long-Term Adherence to COVID-19 Mitigation Recommendations. PLoS One (2021) 16(9):e0257945. doi: 10.1371/journal.pone.0257945</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0257945</ArticleId><ArticleId IdType="pmc">PMC8462713</ArticleId><ArticleId IdType="pubmed">34559863</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidry JPD, Carlyle KE, Miller CA, Ksinan AJ, Winn R, Sheppard VB, et al. . Endorsement of COVID-19 Related Misinformation Among Cancer Survivors. Patient Educ Couns (2022) 105(2):265&#x2013;8. doi: 10.1016/j.pec.2021.05.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pec.2021.05.026</ArticleId><ArticleId IdType="pmc">PMC8139169</ArticleId><ArticleId IdType="pubmed">34030928</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>